WO2019203753A2 - Combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de phosphodiestérase de type 5 et un agent antiémétique - Google Patents

Combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de phosphodiestérase de type 5 et un agent antiémétique Download PDF

Info

Publication number
WO2019203753A2
WO2019203753A2 PCT/TR2018/050806 TR2018050806W WO2019203753A2 WO 2019203753 A2 WO2019203753 A2 WO 2019203753A2 TR 2018050806 W TR2018050806 W TR 2018050806W WO 2019203753 A2 WO2019203753 A2 WO 2019203753A2
Authority
WO
WIPO (PCT)
Prior art keywords
weight
pharmaceutical combination
tablets
combination according
dapoxetine
Prior art date
Application number
PCT/TR2018/050806
Other languages
English (en)
Other versions
WO2019203753A3 (fr
Inventor
Ali TÜRKYILMAZ
Arzu Palantöken
Dicle Güner
Original Assignee
Montero Gida Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Montero Gida Sanayi Ve Ticaret Anonim Sirketi filed Critical Montero Gida Sanayi Ve Ticaret Anonim Sirketi
Priority to EP18915505.4A priority Critical patent/EP3723743A4/fr
Publication of WO2019203753A2 publication Critical patent/WO2019203753A2/fr
Publication of WO2019203753A3 publication Critical patent/WO2019203753A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Definitions

  • the present invention relates to a pharmaceutical combination comprising dapoxetine, a PDE5 inhibitor and furthermore at least one anti-emetic agent.
  • Selective serotonin reuptake inhibitors are used in the long-term prophylaxis of many types of depression, including the endogenous type, recurrent depression, and in the treatment of obsessive-compulsive disorders, panic attack, social phobias, and the bulimia nervosa disease.
  • Dapoxetine was first disclosed in the European patent publication EP0288188B1 is a selective serotonin reuptake inhibitor. Dapoxetine is used for the treatment of depression and premature ejaculation.
  • the IUPAC name of dapoxetine is (S)-N, N-Dimethyl-3-(naphthalen-1 -yloxy)-1 -phenylpropan-1 -amine and has a chemical structure shown with Formula I.
  • dapoxetine is rapidly absorbed and rapidly enters the circulation by almost completely binding to plasma proteins. Therefore, it achieves the peak plasma concentration (C max ) in 1 hour following oral administration.
  • Orally-administered tablets of dapoxetine are commercially available under the name Priligy®, comprising 30 mg or 60 mg dapoxetine per tablet, as well as excipients including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate, hypromellose, titanium dioxide (E171 ), triacetin, black iron oxide (E172) and yellow iron oxide (E172).
  • PDE5 inhibitor phosphodiesterase type 5 inhibitors
  • ED erectile dysfunction
  • PDE5 inhibitors block the phosphodiesterase enzyme in a selective and efficient manner, thus increasing the level of cyclic guanosine monophosphate in the corpus cavernosum smooth muscle cells.
  • Most frequently used PDE5 inhibitors are avanafil, lodenafil, mirodenafil, sildenafil, tadalafil, vardenafil, udenafil, zaprinast, benzamidenafil, dasantafil.
  • Tadalafil is a PDE-5 inhibitor used in the treatment of ED and pulmonary arterial hypertension (PAH). It has a longer half life as compared to other PDE-5 inhibitors (mean, 17,5 hours).
  • Orally-administered tablets of Tadalafil are commercially available under the name Cialis ® , in the strength of 2.5 mg, 5 mg, 10 mg and 20 mg, as well as excipients including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hydroxypropylcellulose, sodium lauryl sulfate, magnesium stearate, hypromellose, titanium dioxide (E171 ), triacetin, yellow iron oxide (E172), talc.
  • IUPAC name of tadalafil is (6R- trans)-6-(1 ,3-benzodioxol-5-yl)- 2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino [1 ',2':1 ,6] pyrido[3,4-b] indole-1 ,4-dione, with the chemical structure illustrated below with Formula II.
  • Formulations comprising a combination of selective serotonin reuptake inhibitors with PDE5 inhibitors are known in the prior art.
  • the patent publication W003000343 discloses the use of a formulation comprising a combination of phosphodiesterase inhibitors and dapoxetine.
  • the anti-emetic agent is used to overcome the disadvantages and side effects of the combinations of dapoxetine and tadalafil meanwhile increasing the therapeutic effect and patient compliance in a desired manner.
  • the main object of the present invention is to provide a combination comprising dapoxetine and a PDE5 inhibitor with at least one anti-emetic agent.
  • the new combinations reduce the side effects when dapoxetine and a PDE5 inhibitor is used together, whilst increasing the therapeutic effect.
  • Another object of the present invention is to provide a pharmaceutical formulation that allows to obtain safe and efficient plasma levels of each pharmacological agents.
  • Another object of the present invention is to provide high stability of the combination and a long shelf life by the help of selection of excipients in a certain ratio.
  • the present invention relates to an easily-administrable combination of dapoxetine and PDE5 inhibitor and anti-emetic agent, eliminating all aforesaid problems and bringing additional advantages to the relevant prior art.
  • dapoxetine refers to not only dapoxetine, but also its other pharmaceutically acceptable salt, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof.
  • PDE5 inhibitor refers to not only PDE5 inhibitor, but also its other pharmaceutically acceptable salt, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof.
  • anti-emetic agent refers to not only anti emetic agent, but also its other pharmaceutically acceptable salt, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof.
  • The“anti-emetic agent” also refers to a drug that is effective against vomiting and nausea. Anti-emetics are typically used to treat motion sickness and the side effects of opioid analgesics, general anaesthetics, and chemotherapy directed against cancer.
  • modified release phase refers to any pharmaceutical formulation that maintain constant levels of a drug in the patient's bloodstream by releasing the drug over an extended period of time modified release is formulated to release the active ingredient gradually and predictably over a 12-hour to 24-hour period.
  • immediate release phase refers to any pharmaceutical formulations that disintegrate rapidly after administration with enhanced rate of dissolution and get dissolved to release the therapeutic effects.
  • the pharmaceutical combination comprises dapoxetine and a PDE5 inhibitor, furthermore at least one anti-emetic agent.
  • the anti-emetic agent reduces the side effect of dapoxetine and tadalafil. Therefore, an improved sexual dysfunction problem has been achieved with the synergistic effect.
  • the ratio of dapoxetine to PDE5 inhibitor is in the range of between 30:1 to 1 :30 by weight or between 20:1 to 1 :20.
  • the ratio of dapoxetine to the anti emetic agent is in the range of between 30:1 to 1 :30 by weight or between 20:1 to 1 :20.
  • the ratio of PDE5 inhibitor to the anti emetic agent is in the range of between 30:1 to 1 :30 by weight or between 20:1 to 1 :20.
  • a PDE5 inhibitor is selected from the group comprising tadalafil, sildenafil, avanafil, lodenafil, mirodenafil, vardenafil, udenafil, zaprinast, benzamidenafil, dasantafil.
  • the PDE5 inhibitor is tadalafil or sildenafil, preferably tadalafil.
  • the anti-emetic agent is selected from the group comprising alizapride, alprazolam, ajwain, aprepitant, benzquinamide, benztropine, betahistine, casopitant, chlorpromazine, cyclizine, dexamethasone, difenidol, dimenhydrinate, diphenhydramine, dolasetron, domperidone, dronabinol, droperidol, emetrol, fosaprepitant, granisetron, haloperidol, hydroxyzine, hyoscine, lorazepam, meclizine, methylprednisolone, metoclopramide, midazolam, mirtazapine, ondansetron, olanzapine, palonosetron, perphenazine, peppermint, prochlorperazine, promethazine, rolapitant, scopolamine, tributine,
  • the anti-emetic agent is selected from the group comprising aprepitant, rolapitant, netupitant, domperidon, metoclopramide, emetrol, tropisetron, difenidol, alizapride, casopitant, lorazepam, mirtazapine, benztropine, alprazolam, granisetron.
  • the anti-emetic agent is selected from the group comprising aprepitant, rolapitant, netupitant, domperidon, metoclopramide.
  • the combination comprises at least one pharmaceutically acceptable excipient is selected from fillers, binders, disintegrants, diluents, dispersing agents, lubricants, glidants, surfactants, plasticizers, preservatives, taste masking, sweeteners, flavoring agents, melting components, inert agent, stabilizers, antioxidants, modified release agents, coating agents, buffering agents, coloring agents or mixtures thereof.
  • Suitable fillers are selected from the group comprising ammonium alginate, calcium carbonate, calcium phosphate, calcium sulfate, cellulose, cellulose acetate, compressible sugar, dextrates, dextrin, dextrose, erythritol, ethylcellulose, fructose, glyceryl palmitostearate, hydrogenated vegetable oil type I, isomalt, kaolin, lactitol, lactose, mannitol, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, microcrystalline cellulose, polydextrose, polymethacrylates, polyvinylpyrrolidone, simethicone, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar spheres, sulfobutylether beta-cyclodextrin, talc, tragacanth, trehalose, polysorbate 80, xylit
  • Suitable binders are selected from the group comprising polyvinylpyrrolidone (povidone), sugars, glucose syrup, natural gums, collagen, proteins such as gelatin, agar, alginates, carbomers, carboxymethylcellulose sodium, cellulose acetate phthalate, chitosan, copovidone, starch, corn starch and pregelatinized starch, starch mucilage, acacia mucilage, dextrates, dextrin, dextrose, ethylcellulose, glyceryl behenate, guar gum, hydrogenated vegetable oil type I, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, liquid glucose, magnesium aluminum silicate, maltodextrin, maltose, methylcellulose, pectin, poloxamer, polycarbophil, polydextrose, polyethylene oxide, polymethacrylates, alumini
  • Suitable disintegrants are selected from the group comprising cross-linked polyvinil pyrrolidone (crospovidone), povidone, cross-linked carboxymethyl cellulose (croscarmellose sodium), low-substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, polyacryline potassium, sodium alginate, corn starch, sodium starch glycolate, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sodium dodesyl sulphate, poloxamer, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
  • cross-linked polyvinil pyrrolidone crospovidone
  • povidone povidone
  • carboxymethyl cellulose croscarmellose sodium
  • low-substituted hydroxypropyl cellulose pregelatinized starch
  • the total amount of disintegrant in the composition is 1.0% to 50.0% by weight, preferably 5.0% to 35.0% by weight and thus desired level of dissolution rate is provided.
  • Suitable diluents are selected from the group comprising microcrystalline cellulose, mannitol, spray-dried mannitol, lactose, lactose monohydrate, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
  • Suitable dispersing agents are selected from the group comprising calcium silicate, magnesium aluminum silicate, sorbitan esters, aluminum oxide, phospholipids, poloxamer or mixtures thereof.
  • Suitable lubricants are selected from the group comprising magnesium stearate, colloidal silicon dioxide, calcium stearate, zinc stearate, talc, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyseryl palmito sulphate, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
  • Suitable glidants are selected from the group comprising talc, aluminium silicate, colloidal silica, calcium silicate, magnesium silicate, magnesium oxide, starch or mixtures thereof.
  • Suitable surfactants are selected from the group comprising sodium lauryl sulfate, cetylpyridinium chloride, docusate sodium, lauric acid, polyoxyethylene sorbitan fatty acid esters (polysorbate), phospholipids, cetrimide or mixtures thereof.
  • Suitable plasticizers are selected from the group comprising polyethylene glycols of different molecular weights, triacetin, tributyl citrate, triethyl citrate, chlorobutanol, dibutyl phthalate, dibutyl sebacate, dimethyl phthalate, glycerin, mannitol, petrolatum and lanolin alcohols, propylene glycol or mixtures thereof.
  • Suitable preservatives are selected from the group comprising methyl paraben, propyl paraben and their salts (such as sodium, potassium), sodium benzoate, benzyl alcohol, citric acid, benzoic acid, m-cresol, phenol or mixtures thereof.
  • the tablets can be coated with coating agents, and mixtures of sweeteners or flavours have been used for masking the bitter taste.
  • suitable sweeteners are selected from the group comprising aspartame, thaumatin, mogroside, erythritol, inulin, potassium acesulfame, sodium saccharinate, neohesperidine dihydrochalcone, sucralose, saccharin, sugars such as sucrose, glucose, lactose, fructose or sugar alcohols such as mannitol, sorbitol, xylitol, erythritol or mixtures thereof.
  • Suitable flavoring agents are selected from the group comprising menthol, peppermint, cinnamon, chocolate, vanillin or fruit essences such as cherry, orange, strawberry, grape, black currant, raspberry, banana, red fruits, wild berries or mixtures thereof.
  • Suitable melting components are selected from gelucire (stearyl macrogolglyceride), poloxamer (polyoxyethylene-polyoxypropylene block copolymer), polyethylene glycol, povidone, soluplus, cationic methacrylate, co-povidone, methacrylic acid copolymers, cellulose acetate phthalate, acetylated monoglyceride, butyl pthalybutyl glycolate, dibutyl tartrate, diethyl phthalate, dimethly phthalate, ethyl phthalylethly glycolate, glycerin, propylene glycol, triacetin, triacetin citrate, tripropionin or mixtures thereof.
  • Suitable inert agents are located between the two molecules wherein the inert agent is selected from starch, lactose, sugar alcohol like D-mannitol, erythritol; lowsubstituted hydroxypropyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, methylcellulose, hydroxyethyl methylcellulose or mixtures thereof.
  • Suitable stabilizers are selected from the group comprising sucrose, citric acid, fumaric acid, tartaric acid, sodium citrate, sodium benzoate, sodium dihydrogen phosphate, calcium carbonate, magnesium carbonate, arginine, lysine, meglamine, ascorbic acid and the stabilizer is preferably, citric acid, fumaric acid, arginine or mixtures thereof.
  • Suitable antioxidants are selected from the group comprising alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), erythorbic acid, monothioglycerol, potassium metabisulfite, propyl gallate, sodium ascorbate, sodium metabisulfite, sodium sulfite, thymol or mixtures thereof.
  • Suitable modified release agents are selected from the group comprising ethyl acrylate, polymethacrylates ( Eudragit ), ethyl methacrylate copolymer, ethylcellulose, methylcellulose, hypromellose phthalate, polydextrose, polyvinylacetate phthalate, zein, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, hydroxypropyl methylcellulose (HPMC), hydroxyethyl cellulose, hydroxymethyl cellulose, gelatin, polyethylene oxide, acacia, dextrin, starch, polyhydroxyethylmethacrylate, sodium carboxymethylcellulose, carboxymethyl cellulose, sodium alginate, alginic acid, pectin, polyglucoronic acid, polygalacturonic acid, chondroitic sulfate, carrageenan, lambda carregeenan, iota carregeenan, furcellaran
  • Suitable coating agent are selected from the group comprising hydroxypropyl methylcellulose, lactose monohydrate, hydroxypropyl cellulose, polyvinyl alcohol (PVA), polyethylene glycol (PEG), talc, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), all kinds of Opadry®, pigments, dyes, titanium dioxide, iron oxide or mixtures thereof.
  • PVA polyvinyl alcohol
  • PEG polyethylene glycol
  • talc polyvinyl alcohol-polyethylene glycol copolymers
  • Karelease® ethylcellulose dispersions
  • PVP-VA polyvinylprolidone
  • PVP-VA polyvinylprolidone-vinyl acetate copolymer
  • Suitable buffering agents are selected from the group comprising alkali metal citrate, citric acid/sodium citrate, tartaric acid, fumaric acid, sorbic acid, citric acid, succinic acid, adipic acid, ascorbic acid, glutaric acid, potassium hydrogen tartrate, sodium hydrogen tartrate, potassium hydrogen phthalate, sodium hydrogen phthalate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, hydrochloric acid/sodium hydroxide or mixtures thereof.
  • the buffering agent is preferably citric acid, fumaric acid, ascorbic acid, sodium dihydrogen phosphate, glycin, glutamic acid or mixtures thereof.
  • Suitable coloring agents are selected from the group comprising ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), poncau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine); iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof.
  • FD&C Food, Drug & Cosmetic
  • the pharmaceutical combination is administered orally.
  • the pharmaceutical combination is in the form of tablet, capsule, strip, syrup, powder, pastilles, sachet, effervescent formulations, pills, coated bead systems, granules, microspheres, dragees, films, orally administrable films, solutions, solids, elixirs, tinctures, suspensions, colloidal dispersions, dispersions, emulsions.
  • the pharmaceutical combination is formulated as tablets comprising compressed tablets, film-coated tablets, orally disintegrating tablets, modified release tablets, coated or uncoated tablets, multilayer tablets, mini tablets, bilayer tablet, buccal tablets, sublingual tablets, effervescent tablets, immediate release tablets, tablets, gastric disintegrating tablets, chewable tablet, dispersing tablet, lozenges or pastilles.
  • the pharmaceutical combination is formulated as tablet.
  • Tablet may comprise of different type of particles, for example; mini-tablets, pellets, granules, powders or mixtures thereof.
  • each type of particle comprises at least one active agent.
  • the pharmaceutical combination is in the form of film-coated tablets, orally disintegrating tablets.
  • One embodiment of this present invention is directed to tablet coating, it is applied, for example by spray-coating with a water-based film coating formulation.
  • the pharmaceutical combination is formulated as capsule.
  • Capsule may comprise of different type of particles, for example mini capsules, powders, granules, mini-tablets, pellets, beads or mixtures thereof and these particles are filled into capsules.
  • Each type of particle comprises at least one active agent.
  • Capsules may comprise of separated compartments and each active ingredient and these particles is filled into each compartment.
  • An embodiment of this present invention is to combine dapoxetine, tadalafil and anti-emetic agent in stable dosage form with desired dissolution profiles.
  • the release rate of dapoxetine is quicker than other SSRI and the drug elimination rate in the serum is also fast, but most of the PDE-5 inhibitors have short T-max, which means that the exhibition of the medicinal effects is fast, and have long half-life, showing extended duration of the medicinal effect.
  • Dapoxetine and PDE-5 inhibitor are used together there has been inconveniences, due to the difference of the duration of these effects, such as they have to be taken at different times to get the combined effect, or there's a discrepancy of the expression of the effects due to the difference of the duration of the effects when they are taken at the same time.
  • the modified release formulation is preferred.
  • Modified release formulations comprise controlled release, sustained release, delayed release, extended release, repeat action system or mixtures thereof.
  • the formulation has an immediate release phase or a modified release phase or mixtures thereof.
  • the pharmaceutical combination of this present invention is able to match the combination of dapoxetine with short half-life and tadalafil with a long half-life, by including two different release profile which are the immediate release and the modified release in tablet or capsule.
  • both of modified release phase and immediate release phase comprises dapoxetine, further comprises at least one pharmaceutically acceptable excipient.
  • the ratio of dapoxetine in modified release phase to dapoxetine in immediate release phase is in the range of between 5:1 to 1 :5 by weight.
  • the pharmaceutical formulation is in the form of tablet comprising the modified release pellets with immediate release granules and pharmaceutically acceptable excipients or vice versa, preferably tablet is coated film layer.
  • the pharmaceutical formulation of the present invention can be prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, wet or dry granulation, hot melt granulation, hot melt extrusion, fluidized bed granulation, extrusion/spheronization, slugging, spray drying and solvent evaporation.
  • the invention relates to a pharmaceutical kit comprising dapoxetine, tadalafil and anti-emetic, in same unit dosage forms (e.g., as a tablet or liquid or powder), said forms being suitable for administration separately, sequentially or simultaneous in effective amounts.
  • the package comprises instructions for use.
  • the kit may optionally further include polyester coil packing material and humectant.
  • composition wherein said formulation comprises at least one of the following drug combinations for combined, separate or sequential administration:
  • Example 1 The combination comprising dapoxetine, a PDE5 inhibitor and an anti- emetic agent at tablet, capsule or orally disintegrating tablets formulation
  • Example 2 Dapoxetine, tadalafil and aprepitant at film- coated tablet formulation
  • Process for preparing the pharmaceutical combination for film-coated tablet comprises the following steps:
  • step (a) granulating with this mixture of step (a) and step (b)
  • Example 3 Dapoxetine, tadalafil and rolapitant at orally disintegrating tablets formulation
  • Process for preparing the pharmaceutical combination for orally disintegrating tablet comprises the following steps:
  • Process for preparing the pharmaceutical combination for capsule comprises the following steps:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de PDE5, ainsi qu'au moins un agent antiémétique.
PCT/TR2018/050806 2017-12-15 2018-12-13 Combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de phosphodiestérase de type 5 et un agent antiémétique WO2019203753A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP18915505.4A EP3723743A4 (fr) 2017-12-15 2018-12-13 Combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de phosphodiestérase de type 5 et un agent antiémétique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201720443 2017-12-15
TR2017/20443 2017-12-15

Publications (2)

Publication Number Publication Date
WO2019203753A2 true WO2019203753A2 (fr) 2019-10-24
WO2019203753A3 WO2019203753A3 (fr) 2020-01-16

Family

ID=68240624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/050806 WO2019203753A2 (fr) 2017-12-15 2018-12-13 Combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de phosphodiestérase de type 5 et un agent antiémétique

Country Status (2)

Country Link
EP (1) EP3723743A4 (fr)
WO (1) WO2019203753A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023179542A1 (fr) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. Dérivés de 5,8-dihydro-1,7-naphtyridine utiles en tant qu'agonistes de glp-1 pour le traitement du diabète
WO2023198140A1 (fr) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
WO2014027980A1 (fr) * 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Formulations de film buccal comprenant de la dapoxétine et du tadalafil

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023179542A1 (fr) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. Dérivés de 5,8-dihydro-1,7-naphtyridine utiles en tant qu'agonistes de glp-1 pour le traitement du diabète
WO2023198140A1 (fr) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1

Also Published As

Publication number Publication date
EP3723743A2 (fr) 2020-10-21
EP3723743A4 (fr) 2021-09-08
WO2019203753A3 (fr) 2020-01-16

Similar Documents

Publication Publication Date Title
ES2743699T3 (es) Forma de dosificación oral de ketamina
EP2698147B1 (fr) Formulation de film oral comprenant du diapoxetine et tadalafil
JP2018500353A (ja) 回腸−空腸薬物送達用組成物
US10350170B2 (en) Solid preparation
JP6288158B2 (ja) 品質が向上した経口製剤
WO2017208136A1 (fr) Composition pharmaceutique de co-cristal de dapagliflozine
KR102239291B1 (ko) 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
WO2019203753A2 (fr) Combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de phosphodiestérase de type 5 et un agent antiémétique
WO2014027981A2 (fr) Formulations de comprimés effervescents de dapoxétine et d'un inhibiteur de pde5
JP5818219B2 (ja) ６，７−不飽和−７−カルバモイルモルヒナン誘導体含有製剤
WO2019074464A2 (fr) Combinaison pharmaceutique comprenant de la dapoxétine et de la phosphodiestérase de type 5
US9561242B2 (en) Doxycycline composition
EP3326619B1 (fr) Compositions pharmaceutiques orales solides comprenant du tenofovir et du emtricitabine
KR20130135611A (ko) Ｐｄｅ-5 억제제를 포함하는 고미 개선된 경구용 조성물
US9566287B2 (en) Pharmaceutical composition of doxycycline with reduced food effect
EP2962684A1 (fr) Formulations de tadalafil se désintégrant par voie orale
US9463196B2 (en) Pharmaceutical composition of doxycycline with reduced food effect
EP2962685B1 (fr) Formulations de tadalafil se désintégrant par voie orale
EP2959889A1 (fr) Formulations de loxoprofen se désintégrant par voie orale
US20160143923A1 (en) Low dose pharmaceutical composition of doxycycline
US20160143924A1 (en) Low dose pharmaceutical composition of doxycycline
WO2019203748A2 (fr) Combinaison comprenant du raloxifène et au moins un agent antipsychotique
US20170151272A1 (en) A novel pharmaceutical composition of sofosbuvir and ribavirin
WO2014035355A1 (fr) Combinaisons pharmaceutiques comprenant un agent actif dérivé de la quinone
WO2019209208A2 (fr) Compositions pharmaceutiques d'ivabradine à libération contrôlée

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018915505

Country of ref document: EP

Effective date: 20200715